Products

Sized to fit.

Pediatric pharmaceuticals are the fastest growing sector and represent a $20 billion market.  Madeira has identified two sizable drug targets for initial development—therapeutic categories in need of real pediatric medicine. 

The first compound, a statin, is already in the development pipeline.  It focuses on a true case of need in a population with an inherited cholesterol gene that often leads to early heart disease.  The second product in our pipeline is for acute chronic pain management, which presents a significant revenue opportunity with an identifiable market of $700 million.

Future products will target large therapeutic categories like diabetes.  Madeira’s business model and executive team have developed an intricate decision tree for the proper identification of drugs to specifically develop for pediatric patients.